We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Reblozyl

News List

FDA Priority Review for supplemental Biologics License Application for Reblozyl® in Adults with Beta Thalassemia AmericanPharmaceuticalReview
December 06, 2021
Bristol Myers Squibb announced that the FDA has accepted for priority review the supplemental Biologics License Application (sBLA) for Reblozyl® (luspatercept-aamt), a first-in-class erythroid maturation agent, for the treatment of anemia in adults...
EC clears new class of anaemia therapy pharmatimes
June 29, 2020
The European Commission has approved BMS’ blood disease therapy Reblozyl (luspatercept) for the treatment of transfusion-dependent anaemia associated with myelodysplastic syndromes (MDS) or beta thalassaemia.
Key pipeline advancements to propel myelodysplastic syndromes market to $2.4 bn by 2028: GlobalData expresspharma
June 29, 2020
Despite the recent surge of development within the MDS space, KOLs argue that the level of unmet need remained dire.
Bristol Myers Squibb, Acceleron get FDA nod for Reblozyl to treat anaemia with lower-risk MDS pharmaceutical-business-review
April 07, 2020
Bristol Myers Squibb (BMS) and Acceleron Pharma have secured approval from the US Food and Drug Administration (FDA) for Reblozyl (luspatercept-aamt) to treat anaemia in adults with lower-risk myelodysplastic syndromes (MDS).